Recent Updates

July 2017

Alzain® capsules 25mg, 50mg, 75mg, 100mg, 150mg, 225mg, 200mg, 300mg has been added into the formulary as a preferred brand of pregabalin and Lyrica® has been removed.

Fiasp® insulin aspart 100 units per 1ml, 10ml vials, 3ml cartridges, and 3ml FlexTouch® prefilled devices have been added into the formulary for use in patients aged 18 years and over. Please see the formulary for further information.

Lecicarbon A suppositories have been added into the formulary for the management of chronic constipation, following a commissioning decision from the Clinical Policy Committee. Please see the formulary for further information.

Ralvo® medicated plasters 700mg (5% w/w) have been added as a preferred brand of lidocaine plasters, for the treatment of post-herpetic neuralgia, and should only be used following initiation by the Pain Clinic. Please see the formulary for further information.

Sodium oxybate oral solution 500mg in 1ml has been added into the formulary for the management of narcolepsy with cataplexy in adults aged 19 years and older, in line with specific criteria, following a commissioning decision from the Clinical Policy Committee. Please see the formulary for further information.

Emergency contraception: The guidance for emergency contraception has been reviewed and updated, following new advice from The Faculty of Sexual and Reproductive Healthcare (FSRH) Please see the formulary for up to date guidance. Ulipristal acetate tablets 30mg has been reclassified as green first line preferred treatment of emergency contraception, and Levonorgestrel tablets 1.5mg has been reclassified as blue second line treatment, following the update. Please see the formulary for further information.

Management of epilepsy: The guidance has been refreshed and expanded to emphasise MHRA Drug Safety Updates. Please see the formulary for up to date guidance and further information.

May 2017

Nystan® has been removed as the preferred brand of nystatin 100,00 units/ml and generic prescribing is now recommended. The dose has reverted to 1ml four times a day in line with the recently updated BNF and BNFc.

Omeprazole orodispersible tablets have been added into the formulary, only for use in children.

Evolve® HA 0.2% P/F eye drops have been added as a preferred brand of sodium hyaluronate preservative free and Hyabak® and Hylo-forte® have been removed from the formulary.

Glucodrate® oral powder sachets have been added into the formulary only for patients with short bowel syndrome who are unable to tolerate St Mark's Electrolyte Solution.

Sacubitril/ valsartan tablets has been reclassified as amber for use in primary care. Treatment should be initiated by a heart failure consultant. Initial clinical assessment, monitoring and prescribing will remain the responsibility of the specialist heart failure team for at least the first three months. Please see the formulary for further information.

Management of thyroid disorders guidance: This has been added into the formulary. Please refer to the formulary for this guidance.

IBS guidance: The guidance for irritable bowel syndrome in adults has been reviewed and updated. Please see the formulary for up to date guidance.

March 2017

Spiriva® Handihaler® has been removed from the formulary, leaving Spiriva® Respimat® and Braltus® Zonda® as options for patients requiring tiotropium.

Naloxegol has been reclassified as amber for use in primary care following recommendation from a member of the palliative care team only. In all other indications, naloxegol should be restricted to secondary care use.

PumpCart® Novorapid insulin aspart cartridges - these cartridges are for use in insulin pumps. PumpCart® cartridges have been reclassified as amber to enable continued prescribing by primary care following specialist initiation.

 

Home > Formulary > Updates > Recent Updates

 

  • First line
  • Second line
  • Specialist
  • Hospital